Vivacellebio 20logo
Reduced 20vivacellebio 20logo

Vivacelle Bio, Inc. - VBI

VBI has an IV phospholipid nanoparticle based fluid for refractory & hypovolemic shock . Est. $13 billion market, quick FDA pathway. Patents. Can relocate.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Chicago, IL, US
  • Currency USD
  • Founded August 2013
  • Employees 6
  • Incorporation Type C-corp
  • Website

Company Summary

Vivacelle Bio, has developed VBI-1, a phospholipid nanoparticle injectable to sustain life after severe injury causing hypovolemic shock. Competing products have toxicity and are more expensive. The formulation is based on non-toxic FDA-approved products that qualifies VBI-1 for an expedited FDA pathway. Preclinical studies show safety efficacy and protection from reperfusion injury. Experienced management. $13 billion addressable market.


  • 97aabd67 bfec 4565 9ca2 25ed9dd06639
    President and Chief Innovation Officer

    Dr. Simpkins is the inventor of Vivacelle. He is also a trauma surgeon and scientist with over thirty years of experience including serving as Director of the Trauma Program at LSU Health Sciences Center in Shreveport, LA. He achieved the rank of Commander and received two commendations for excellence in research while serving in the U.S. Navy which included several scientific discoveries and publications. MD- Harvard, BA-Amherst College

  • A51aff67 2f0e 4995 9819 b9c35c69cf59
    Chief Legal and Operating Officer

    Dr. DeShield is a pharmaceutical, biomedical and life sciences intellectual property attorney with more than eight years' experience. He is well-versed in Intellectual Property, patent litigation, patent prosecution, preparation, and trade secrets. His experience also encompasses food and drug law, regulatory law, anti-trust, contract, corporate and commercial law.
    Ph.D Biochemistry SUNY Buffalo School of Medicine, J.D. SUNY Buffalo Law School

  • E70a22c8 907e 43b4 9a2a 7a350938f844
    Chief Medical Officer

    Dr.. Talluri is the owner of Compass Consulting International. She has over eighteen years of experience in drug development and medical affairs including stints at Johnson & Johnson, CATO, Lundbeck and Talecris Biotherapeutics. Her experience includes successful IND's and NDA's in CNS, neuroimmunology, immunology, pulmonary, oncology and other indications. Psychiatry Residency- Duke University Emergency Medicine-St. Lucia

  • Fbb2c2f8 b095 481c 9860 786c13b3e26e
    Chief Executive Officer

    25 years in biotech and pharma senior management, including President and COO at Panacea Pharma and Antex Biologics, VP North American Vaccine, and senior roles at Merck & Co. Success in raising capital for private and public companies. Experience in small molecules, vaccines, monoclonal antibodies, and cancer diagnostics, as well as marketing and sales, and business development


  • Default avatar
    Thomas Fitzgerald M.B.A.

Previous Investors

  • Default avatar
    Ron Damper